Louisiana State Employees Retirement System Acquires Shares of 87,300 Exelixis, Inc. (NASDAQ:EXEL)

Louisiana State Employees Retirement System acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 87,300 shares of the biotechnology company’s stock, valued at approximately $2,094,000.

A number of other institutional investors have also recently bought and sold shares of the business. NewEdge Wealth LLC grew its stake in Exelixis by 45.4% in the 4th quarter. NewEdge Wealth LLC now owns 681,104 shares of the biotechnology company’s stock valued at $16,340,000 after purchasing an additional 212,553 shares during the period. Nisa Investment Advisors LLC grew its stake in Exelixis by 87.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 8,140 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 3,800 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Exelixis by 5.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,470 shares of the biotechnology company’s stock valued at $827,000 after purchasing an additional 1,853 shares during the period. DekaBank Deutsche Girozentrale lifted its position in shares of Exelixis by 55.8% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 380,093 shares of the biotechnology company’s stock valued at $9,065,000 after buying an additional 136,194 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its position in shares of Exelixis by 2.6% during the 4th quarter. New York State Teachers Retirement System now owns 421,377 shares of the biotechnology company’s stock valued at $10,109,000 after buying an additional 10,617 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Up 0.2 %

NASDAQ:EXEL opened at $22.87 on Thursday. The business’s 50-day moving average price is $22.40 and its two-hundred day moving average price is $22.13. Exelixis, Inc. has a twelve month low of $18.08 and a twelve month high of $24.34. The stock has a market cap of $6.93 billion, a P/E ratio of 35.73, a PEG ratio of 0.60 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.02. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. The firm had revenue of $479.65 million for the quarter, compared to analysts’ expectations of $481.23 million. On average, equities research analysts expect that Exelixis, Inc. will post 1.21 EPS for the current fiscal year.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 47,020 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $21.45, for a total value of $1,008,579.00. Following the sale, the executive vice president now owns 384,866 shares of the company’s stock, valued at approximately $8,255,375.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Patrick J. Haley sold 47,020 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the transaction, the executive vice president now directly owns 384,866 shares in the company, valued at approximately $8,255,375.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alan M. Garber sold 19,205 shares of the stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $24.01, for a total value of $461,112.05. Following the transaction, the director now owns 35,703 shares in the company, valued at $857,229.03. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on EXEL shares. JMP Securities reaffirmed a “market outperform” rating and set a $27.00 price target on shares of Exelixis in a research report on Wednesday, April 10th. TheStreet raised Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. Barclays cut Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price target on the stock. in a research report on Thursday, April 11th. Royal Bank of Canada upped their price target on Exelixis from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Finally, Stifel Nicolaus increased their price objective on Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Exelixis currently has a consensus rating of “Moderate Buy” and an average price target of $26.29.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.